Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

NCT03591575 is registered in ClinicalTrials.gov with Chiesi Canada Corp as lead sponsor.

NCT NCT03591575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03591575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia
Lead sponsor
Chiesi Canada Corp
Phase
Phase 4
Overall status
Completed
Start date
November 9, 2018
Completion date
September 29, 2020
Enrollment
64 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

beta thalassemia major anemia, iron overload